Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
Primary central nervous system lymphoma (PCNSL) is a rare form and aggressive type of diffuse large B-cell lymphoma (DLBCL) that occurs in both immunocompetent and immunocompromised adults. While adding rituximab to chemotherapeutic regimens resulted in dramatic improvement in both progression-free...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2023-01-01
|
| Seri Bilgileri: | Frontiers in Oncology |
| Konular: | |
| Online Erişim: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1082235/full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|